• Emre Durdag, Zuhal Yildirim, Nese Lortlar Unlu, Aydemir Kale, and Necdet Ceviker.
• Department of Neurosurgery, Faculty of Medicine, Gazi University, Besevler, Ankara, Turkey.
• World Neurosurg. 2018 Dec 1; 120: e33-e41.

ObjectiveSpinal cord ischemia is a serious and catastrophic clinicopathologic condition. Despite studies reported over the last 20 years, alternative and efficient treatment options remain unclear. We examined the neuroprotective effects of vigabatrin on a spinal ischemia-reperfusion model.MethodsWe divided 24 New Zealand rabbits into 4 groups (control, ischemia reperfusion, and low-dose and high-dose vigabatrin). The control group underwent only abdominal surgery, whereas an abdominal aortic cross-clamp model of spinal ischemia was performed in the other groups. Clips were removed after 30 minutes and 50 and 150 mg/kg vigabatrin was administered intraperitoneally to the low-dose and high-dose groups, respectively. Neurologic examination was performed for 48 hours, after which the rabbits were sacrificed and a blood sample obtained. Biochemical examination of malondialdehyde, advanced oxidation protein products, total nitric oxide, and glutathione levels and superoxide dismutase activities in plasma and tissue sample, and histopathologic examination of the spinal cord were performed and statistical results compared between the groups.ResultsLow-dose vigabatrin had statistically significant effects of neuroprotection on spinal ischemia. Although high-dose vigabatrin had similar effects, the results were not statistically significant for all parameters of biochemical analysis. In addition, histopathologic examination showed some toxic effects of high-dose vigabatrin.ConclusionsNeuroprotective effects of vigabatrin are shown. For clinical use, further studies are needed.Copyright © 2018. Published by Elsevier Inc.

33 keywords...

hide…